Mahoney Shares What Surprised Him at Boston Scientific and How …

What steps did Boston Scientific – under Mahoney’s leadership – take to unlock such significant growth? In an interview at the Medtech Conference, Mahoney – interviewed by Kevin Hykes, …

7%
OFF

Mahoney Takes The Reins At Boston Sci

1 week from now

Nov 1, 2012 · Mahoney steps in amid Boston Sci's reinvention project, as the company took a $3.4 billion loss in the second quarter and followed it up with a 7% year-over-year sales …

fiercebiotech.com

$5.23
OFF

Mike Mahoney Takes Over As Chief Executive Of Boston Scientific ...

1 week from now

Nov 1, 2012 · Boston Scientific shares advanced 9 cents to $5.23 on Mahoney’s first day on the job Thursday, an increase of 1.7 percent on the New York Stock Exchange.

boston.com

FAQs about Mahoney Shares What Surprised Him at Boston Scientific and How … Coupon?

Why did Michael Mahoney join Boston Scientific?

Michael Mahoney, the chairman and CEO of Boston Scientific, says he joined the firm because he saw an incredible opportunity at a company with a $7 billion market cap that hadn’t grown in five years. Today, Boston Scientific’s market cap tops $37 billion. ...

Is Boston Scientific a big deal-maker under Mike Mahoney?

Boston Scientific has become a big deal-maker under chief executive Mike Mahoney. – Topher Cox For over a decade before the Guidant bidding war, Boston Scientific had been an aggressive deal-maker. The pacemakers and defibrillators from that acquisition made Boston Scientific one of the biggest players in the cardiovascular sector. ...

Is Mahoney taking performance to the next level?

“We’re taking our performance to the next level,” Mahoney said. “ We have high aspirations for the company, but we want to do so while always maintaining a great culture — a caring culture for our employees — doing the right things for society w hile, hopefully, delivering a unique set of financials along the way.” ...

Why did Mahoney change the labeling on incontinence products?

Eventually, in 2021, it reached a $189 million settlement with multiple state attorneys general to change the labeling on its incontinence products, in part to clarify their potential risks. Before Mahoney’s arrival, the company focused on dominating cardiology, Butcher said. ...

How does Boston Scientific reinvest its money?

Boston Scientific developed a system: Set aside 10 percent of revenue for research and development, including to advance already acquired technologies, and devote much of its profits to new deals. “Pretty much every dollar that the company earns, we reinvest back into internal R&D and technology acquisition,” Butcher said. ...

How big is Boston Scientific's market capitalization?

Boston Scientific’s market capitalization has grown nearly 10 times larger since Mike Mahoney joined as CEO in 2011. He shared key insights about corporate strategy at DeviceTalks Boston in May. ...